[{"from": "human", "value": "What can you tell me about this molecule? [C][=C][C][C@@][C][C][C][N][Ring1][Branch1][C][=Branch1][C][=O][C][N][C][Ring1][#Branch2][=O]"}, {"from": "gpt", "value": "The molecule is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been chemically modified to increase its half-life, stability, and oral bioavailability. It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and Pitt Hopkins Syndromes. It was granted Orphan Drug Designation by the FDA in October 2019 and was granted a patent by the European Patent Office in December 2019. Clinical trials are expected to begin in 2020."}]